Комплексный подход к ведению пациенток с климактерическим синдромом: терапия и профилактика с учетом новых патогенетических механизмов

Климактерический синдром (КС) представляет собой комплексное состояние, выходящее за рамки лишь вазомоторных симптомов (ВМС) и включающее психоэмоциональные расстройства, нарушения сна, метаболические нарушения, повышенные риски соматической патологии. Эти изменения затрагивают до 97,5% женщин в пери- и постменопаузе, ухудшают качество жизни и повышают риски сердечно-сосудистых, нейродегенеративных и онкологических заболеваний. В обзоре представлен анализ наиболее актуальных данных международных электронных библиографических и научных баз PubMed, Scopus, Web of Science, eLIBRARY.RU, а также ресурсы Кохрейновской библиотеки и научные публикации в рецензируемых медицинских журналах. Акцентируется внимание на ряде недостаточно освещенных патофизиологических аспектов постменопаузальных нарушений, включая механизмы сужения термонейтральной зоны гипоталамуса, дисфункции серотонинергической и норадренергической нейротрансмиттерных систем, роли оксидативного стресса и снижения активности антиоксидантных ферментов, повреждения ДНК и канцерогенеза, развития дислипидемии, инсулинорезистентности и эндотелиальной дисфункции. В рамках обзора подробно аргументируется необходимость внедрения комплексного терапевтического подхода КС, который направлен не на изолированное купирование симптомов, а на одновременную коррекцию ключевых взаимосвязанных патогенетических звеньев. В работе представлен детальный анализ современных фундаментальных и клинических данных, демонстрирующих эффективность различных активных молекул, включая β-аланин, изофлавоны, 5-гидрокситриптофан, витамины С, Е и группы B. Рассмотрено их воздействие на стабилизацию центра терморегуляции в гипоталамусе, селективную модуляцию эстрогеновых рецепторов, улучшение липидного спектра и чувствительности к инсулину, а также на восстановление концентрации серотонина, гомоцистеина и супрессию оксидативного стресса. Многокомпонентная стратегия ведения пациенток обеспечивает не только эффективный симптоматический контроль вазомоторных и психоэмоциональных проявлений КС, но и долгосрочную профилактику сердечно-сосудистых, метаболических и нейродегенеративных осложнений, реализуя принципы активного долголетия женщин.

1. Avis NE, Crawford SL, Green R. Vasomotor Symptoms Across the Menopause Transition: Differences Among Women. Obstet Gynecol Clin North Am. 2018;45(4):629–640. https://doi.org/10.1016/j.ogc.2018.07.005.

2. Сметник АА, Иванов ИА, Ермакова ЕИ, Табеева ГИ. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. Акушерство и гинекология. 2025;(8):196–208. https://doi.org/10.18565/aig.2025.200.

3. Jia Y, Zhou Z, Xiang F, Hu W, Cao X. Global prevalence of depression in menopausal women: A systematic review and meta-analysis. J Affect Disord. 2024;358:474–482. https://doi.org/10.1016/j.jad.2024.05.051.

4. Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women’s cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2023;19(2):458–466. https://doi.org/10.5114/aoms/157308.

5. Doshi SB, Agarwal A. The role of oxidative stress in menopause. J Midlife Health. 2013;4(3):140–146. https://doi.org/10.4103/0976-7800.118990.

6. Li J, Liu F, Liu Z, Li M, Wang Y, Shang Y et al. Prevalence and associated factors of depression in postmenopausal women: a systematic review and meta-analysis. BMC Psychiatry. 2024;24(1):431. https://doi.org/10.1186/s12888-024-05875-0.

7. Freeman EW. Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population. Womens Midlife Health. 2015;1(1):2. https://doi.org/10.1186/s40695-015-0002-y.

8. McKinlay SM, Brambilla DJ, Posner JG. “Reprint of” The normal menopause transition. Maturitas. 2008;61(1-2):4–16. https://doi.org/10.1016/j.maturitas.2008.09.005.

9. Huang S, Wang Z, Zheng D, Liu L. Anxiety disorder in menopausal women and the intervention efficacy of mindfulness-based stress reduction. Am J Transl Res. 2023;15(3):2016–2024. Available at: https://e-century.us/files/ajtr/15/3/ajtr0148421.pdf1.

10. Vaziri‐Harami R, Kazemi SN, Vaziri‐harami S, Hazari V, Farokh P, Valadbeigi T. The prevalence of depression and anxiety in premenopausal and menopausal women: A cross‐sectional study. Health Sci Rep. 2024;7(7):e2267. https://doi.org/10.1002/hsr2.2267.

11. Salari N, Hasheminezhad R, Hosseinian-Far A, Rasoulpoor S, Assefi M, Nankali S et al. Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep Breath. 2023;27(5):1883–1897. https://doi.org/10.1007/s11325-023-02793-5.

12. Skibiak K, Dębski J, Przybyłowski J, Walędziak M, Różańska-Walędziak A. The influence of menopausal status on sleep quality in different populations – a narrative review. Menopausal Review. 2025;24(1):53–65. https://doi.org/10.5114/pm.2025.150450.

13. Jeon G-H. Insomnia in Postmenopausal Women: How to Approach and Treat It? J Clin Med. 2024;13(2):428. https://doi.org/10.3390/jcm13020428.

14. Yu Y, Yapeng H, Liu Z, Fang L, Li J, Luan Y et al. Mitochondrial dysfunction in perimenopausal mood disorders: From hormonal shifts to neuroenergetic failure (Review). Int J Mol Med. 2025;56(6):215. https://doi.org/10.3892/ijmm.2025.5656.

15. Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina. 2019;55(10):668. https://doi.org/10.3390/medicina55100668.

16. Forma E, Urbańska K, Bryś M. Menopause Hot Flashes and Molecular Mechanisms Modulated by Food-Derived Nutrients. Nutrients. 2024;16(5):655. https://doi.org/10.3390/nu16050655.

17. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health. 2010;2:123–135. https://doi.org/10.2147/IJWH.S7721.

18. Wang H, Sun Y, Wang W, Wang X, Zhang J, Bai Y et al. Mapping the 5-HTergic neural pathways in perimenopausal mice and elucidating the role of oestrogen receptors in 5-HT neurotransmission. Heliyon. 2024;10(6):e27976. https://doi.org/10.1016/j.heliyon.2024.e27976.

19. Gombert-Labedens M, Vesterdorf K, Fuller A, Maloney SK, Baker FC. Effects of menopause on temperature regulation. Temperature. 2025;12(2):92–132. https://doi.org/10.1080/23328940.2025.2484499.

20. Rekkas PV, Wilson AA, Lee VWH, Yogalingam P, Sacher J, Rusjan P et al. Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11–Labeled Harmine Positron Emission Tomography. JAMA Psychiatry. 2014;71(8):873. https://doi.org/10.1001/jamapsychiatry.2014.250.

21. Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):190. https://doi.org/10.1038/s41392-025-02253-4.

22. Sánchez-Rodríguez MA, Zacarías-Flores M, Arronte-Rosales A, Mendoza--Núñez VM. Association between hot flashes severity and oxidative stress among Mexican postmenopausal women: A cross-sectional study. PLoS ONE. 2019;14(9):e0214264. https://doi.org/10.1371/journal.pone.0214264.

23. Chandankhede M, Gupta M, Pakhmode S. Assessment of Psychological Status and Oxidative Stress in Postmenopausal Women: A Cross-Sectional Study. J Menopausal Med. 2021;27(3):155. https://doi.org/10.6118/jmm.20035.

24. Liang G, Kow ASF, Yusof R, Tham CL, Ho Y-C, Lee MT. Menopause--Associated Depression: Impact of Oxidative Stress and Neuroinflammation on the Central Nervous System – A Review. Biomedicines. 2024;12(1):184. https://doi.org/10.3390/biomedicines12010184.

25. Vassalle C. On oxidative status and cardiovascular risk in women: Keeping pink at heart. World J Cardiol. 2009;1(1):26. https://doi.org/10.4330/wjc.v1.i1.26.

26. Choi Y-J, Kim GS. Transitions in metabolic syndrome clustering patterns before and after menopause: a latent transition analysis in Korean women. Menopause. 2026;33(4):449–459. https://doi.org/10.1097/GME.0000000000002689.

27. Leanza G, Conte C, Cannata F, Isgrò C, Piccoli A, Strollo R et al. Oxidative Stress in Postmenopausal Women with or without Obesity. Cells. 2023;12(8):1137. https://doi.org/10.3390/cells12081137.

28. Fang K, Dong H, Wang D, Gong J, Huang W, Lu F. Soy isoflavones and glucose metabolism in menopausal women: A systematic review and meta‐analysis of randomized controlled trials. Mol Nutr Food Res. 2016;60(7):1602–1614. https://doi.org/10.1002/mnfr.201501024.

29. Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. 2011;93(2):356–367. https://doi.org/10.3945/ajcn.110.008359.

30. Mao C, Yuan J-Q, Lv Y-B, Gao X, Yin Z-X, Kraus VB et al. Associations between superoxide dismutase, malondialdehyde and all-cause mortality in older adults: a community-based cohort study. BMC Geriatr. 2019;19(1):104. https://doi.org/10.1186/s12877-019-1109-z.

31. Abulajiang Y, Liu T, Wang M, Abulai A, Wu Y. The influence of menopause age on gynecologic cancer risk: a comprehensive analysis using NHANES data. Front Oncol. 2025;15:1541585. https://doi.org/10.3389/fonc.2025.1541585.

32. Dibaba DT, Ogunsina K, Braithwaite D, Akinyemiju T. Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype. Breast Cancer Res Treat. 2019;174(1):209–218. https://doi.org/10.1007/s10549-018-5056-8.

33. Stachowiak G, Pertyński T, Pertyńska-Marczewska M. Metabolic disorders in menopause. Menopausal Review. 2015;1:59–64. https://doi.org/10.5114/pm.2015.50000.

34. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25(10):1155–1164. https://doi.org/10.1097/GME.0000000000001136.

35. Торшин ИЮ, Громова ОА, Лиманова ОА. Быстрый эффект клималанина (β-аланина) при приливах: сравнительное исследование взаимодействий бета-аланина, таурина и глицина с глициновыми рецепторами. Гинекология. 2012;14(2):65–69. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/33323.

36. Громова ОА, Торшин ИЮ, Лиманова ОА, Никонов АА. Патофизиология вегетативно-сосудистых пароксизмов (приливы) у женщин в период менопаузы и механизм действия β-аланина. Новая клинико-фармакологическая концепция. Гинекология. 2010;12(2):29–36. Режим доступа: https://medi.ru/info/950.

37. Зароченцева НВ, Джиджихия ЛК. Возможности применения клималанина при вазомоторных пароксизмах у женщин в климактерическом периоде. Российский вестник акушера-гинеколога. 2012;12(3):92–97. Режим доступа: https://www.mediasphera.ru/issues/rossijskij-vestnikakushera-ginekologa/2012/3/031726-61222012320.

38. Евтушенко ИД, Петров ИА, Петрова МС, Ткачев ВН, Кисляк СВ. Применение β-аланина для терапии дефицита эстрогенов при хирургической менопаузе. Акушерство и гинекология. 2014;(4):93–95. Режим доступа: https://aig-journal.ru/articles/Primenenie-alanina-dlya-terapiideficita-estrogenov-pri-hirurgicheskoi-menopauze.html.

39. Schneider MN. Nature’s Relief: Efficacy of Plant-Based Therapies vs. Placebo in Easing Vasomotor Menopausal Symptoms. Nursing Capstones. 2025;383:1–24. Available at: https://commons.und.edu/nurs-capstones/383.

40. Biniwale P, Biniwale V, Phadke A, Qamra A. Soy isoflavones in postmenopausal women: a review of current evidence. Am J Clin Exp Obstet Gyneco. 2022;8(1):1–13. Available at: https://e-century.us/files/ajceog/8/1/ajceog0144070.pdf.

41. Luan H, Liu Q, Guo Y, Fan H, A S, Lin J. Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and metaanalysis. PeerJ. 2025;13:e19715. https://doi.org/10.7717/peerj.19715.

42. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms – A systematic review. Mol Nutr Food Res. 2009;53(9):1084–1097. https://doi.org/10.1002/mnfr.200800552.

43. Mbu RE, Abauleth YR, Koffi A, Keita N, Dolo A, Lankoande J. Effect of daily supplementation of soy isoflavones on hot flashes and night sweats in African menopausal women. Open J Obstet Gynecol. 2014;4(1):42–46. https://doi.org/10.4236/ojog.2014.41008.

44. Prediger CC da C, Olinto MTA, Nácul LC, Ziegler DR, Pattussi MP. Effects of soy protein containing isoflavones on women’s lipid profile: a metaanalysis. Revista de Nutrição. 2011;24(1):161–172. https://doi.org/10.1590/S1415-52732011000100016.

45. Yang S, Zeng Q, Huang X, Liang Z, Hu H. Effect of Isoflavones on Blood Lipid Alterations in Postmenopausal Females: A Systematic Review and Meta-Analysis of Randomized Trials. Adv Nutr. 2023;14(6):1633–1643. https://doi.org/10.1016/j.advnut.2023.09.008.

46. Mannino G, Serio G, Gaglio R, Maffei ME, Settanni L, Di Stefano V et al. Biological Activity and Metabolomics of Griffonia simplicifolia Seeds Extracted with Different Methodologies. Antioxidants. 2023;12(9):1709. https://doi.org/10.3390/antiox12091709.

47. Murray MT. 5-Hydroxytryptophan. In: Textbook of Natural Medicine. Elsevier; 2013, pp. 820–832. https://doi.org/10.1016/B978-1-4377-2333-5.00098-5.

48. Maffei ME. 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. Int J Mol Sci. 2020;22(1):181. https://doi.org/10.3390/ijms22010181.

49. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutr Rev. 2020;78(1):77–88. https://doi.org/10.1093/nutrit/nuz039.

50. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198. https://doi.org/10.1002/14651858.CD003198.

51. Sutanto CN, Xia X, Heng CW, Tan YS, Lee DPS, Fam J et al. The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial. Clin Nutr. 2024;43(3):593–602. https://doi.org/10.1016/j.clnu.2024.01.010.

52. Iqbal Kh, Alam Kh, Khattak MMA. Biological Significance of Ascorbic Acid (Vitamin C) in Human Health – A Review. Pak J Nutr. 2003;3(1):5–13. https://doi.org/10.3923/pjn.2004.5.13.

53. El Mashad GM, ElSayed HM, Nosair NA. Effect of vitamin C supplementation on lipid profile, serum uric acid, and ascorbic acid in children on hemodialysis. Saudi J Kidney Dis Transpl. 2016;27(6):1148–1154. https://doi.org/10.4103/1319-2442.194602.

54. McRae MP. Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. J Chiropr Med. 2008;7(2):48–58. https://doi.org/10.1016/j.jcme.2008.01.002.

55. Montoya-Estrada A, García-Cortés AY, Romo-Yañez J, Ortiz-Luna GF, Arellano-Eguiluz A, Belmont-Gómez A et al. The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women – A Pilot Randomized Clinical Trial. Nutrients. 2024;16(21):3775. https://doi.org/10.3390/nu16213775.

56. Ozemek C, Hildreth KL, Groves DW, Moreau KL. Acute ascorbic acid infusion increases left ventricular diastolic function in postmenopausal women. Maturitas. 2016;92:154–161. https://doi.org/10.1016/j.maturitas.2016.08.007.

57. Vijayakumar TM, Pavitra K, Muthunarayanan L. Comparative assessment of methylcobalamin and ascorbic acid on cognitive function in postmenopausal women – A randomized, double-blind trial. Contemp Clin Trials Commun. 2017;8:175–180. https://doi.org/10.1016/j.conctc.2017.10.006.

58. Farshbaf-Khalili A, Ostadrahimi A, Mirghafourvand M, Ataei-Almanghadim K, Dousti S, Iranshahi AM. Clinical Efficacy of Curcumin and Vitamin E on Inflammatory-Oxidative Stress Biomarkers and Primary Symptoms of Menopause in Healthy Postmenopausal Women: A Triple-Blind Randomized Controlled Trial. J Nutr Metab. 2022;2022:6339715. https://doi.org/10.1155/2022/6339715.

59. Feduniw S, Korczyńska L, Górski K, Zgliczyńska M, Bączkowska M, Byrczak M et al. The Effect of Vitamin E Supplementation in Postmenopausal Women – A Systematic Review. Nutrients. 2022;15(1):160. https://doi.org/10.3390/nu15010160.

60. Takahashi M, Miyashita M, Park JH, Kawanishi N, Bae SR, Nakamura Y et al. Low-volume exercise training and vitamin E supplementation attenuates oxidative stress in postmenopausal women. J Nutr Sci Vitaminol. 2013;59(5):375–383. https://doi.org/10.3177/jnsv.59.375.

61. Milart P, Woźniakowska E, Wrona W. Selected vitamins and quality of life in menopausal women. Men Rev. 2018;17(4):180–184. https://doi.org/10.5114/pm.2018.81742.

62. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of Homocysteine-Lowering Treatment With Folic Acid and B Vitamins on Risk of Type 2 Diabetes in Women. Diabetes. 2009;58(8):1921–1928. https://doi.org/10.2337/db09-0087.

63. Pan L, Jaroenporn S, Yamamoto T, Nagaoka K, Azumano I, Onda M et al. Effects of pantothenic acid supplement on secretion of steroids by the adrenal cortex in female rats. Reprod Med Biol. 2012;11(2):101–104. https://doi.org/10.1007/s12522-011-0113-6.

64. Lü J, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med. 2010;14(4):840–860. https://doi.org/10.1111/j.1582-4934.2009.00897.x.

65. Ramos-Tovar E, Muriel P. Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver. Antioxidants. 2020;9(12):1279. https://doi.org/10.3390/antiox9121279.

66. Trimarco V, Rozza F, Izzo R, De Leo V, Cappelli V, Riccardi C, Di Carlo C. Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial. Int J Womens Health. 2016;8:581–587. https://doi.org/10.2147/IJWH.S115948.

67. Ших ЕВ, Гребенщикова ЛЮ. Рациональная дотация микронутриентов как способ повышения качества жизни у пациенток с климактерическим синдромом. Медицинский cовет. 2017;(13):166–171. https://doi.org/10.21518/2079-701X-2017-13-166-171.